Cymbalta
Product Images NDC 68151-4734

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Cymbalta (NDC 68151-4734). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Cymbalta 01)

Chemical structure diagram of the active ingredient in Cymbalta, showing a bicyclic phenyl and naphthalene moiety connected to a chiral carbon with a thiophene ring and an amine group indicated as NH·HCl CH3.*

FDA Label Image

Figure 3 (Cymbalta 02)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: CYM 60 mg BID, CYM 60 mg QD, CYM 20 mg QD, and placebo. The percentage of patients improved decreases as percent improvement in pain increases across all groups, with placebo consistently showing the lowest improvement rates.*

FDA Label Image

Figure 4 (Cymbalta 03)

A line graph showing the percentage of patients improved against percent improvement in pain from baseline. It compares three groups: Cymbalta 60 mg twice daily (BID), Cymbalta 60 mg once daily (QD), and placebo, indicating the pain improvement distribution for each group across a range of improvement percentages.*

FDA Label Image

Figure 5 (Cymbalta 13)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for three groups: Cymbalta 60mg twice daily, Cymbalta 60mg once daily, and placebo. The y-axis represents the percentage of patients improved, while the x-axis shows the percent improvement in pain from baseline, ranging from greater than 0 to 100.*

FDA Label Image

Figure 6 (Cymbalta 14)

A line graph depicting the percentage of patients improved in pain from baseline at different percent improvement levels. The graph compares Cymbalta dosages of 20 mg, 60 mg, and 120 mg once daily against a placebo, showing higher percentages of improvement for all Cymbalta dosages compared to placebo across the range.*

FDA Label Image

Figure 7 (Cymbalta 15)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Cymbalta (CYM60/120 mg once daily) and placebo. The vertical axis shows the percentage of patients improved, while the horizontal axis shows percent improvement in pain, ranging from >0 to 100. Cymbalta's curve shows consistently higher patient improvement percentages than placebo across the pain improvement scale.*

FDA Label Image

Figure 8 (Cymbalta 16)

A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Cymbalta 60 mg once daily and placebo. The graph shows two lines with data points representing the treatment and placebo groups across different improvement thresholds.*

FDA Label Image

Figure 9 (Cymbalta 17)

A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Cymbalta (120 mg once daily). The y-axis represents the percentage of patients improved, while the x-axis shows the percent improvement in pain, ranging from greater than 0 to 100 percent. Two lines depict the data: one for placebo and one for Cymbalta, with Cymbalta showing higher patient improvement percentages across pain improvement levels.*

FDA Label Image

Figure 1 (Cymbalta 18)

A line graph depicting the proportion of patients with relapse over time from randomization to relapse (days). It compares two treatments: placebo and Cymbalta, showing the proportion of patients relapsing over approximately 200 days. The placebo group exhibits a higher proportion of relapse compared to the Cymbalta group throughout the time period.*

FDA Label Image

Figure 2 (Cymbalta 19)

A line graph depicting the proportion of patients with relapse over time from randomization in days for Cymbalta compared to placebo. The x-axis represents time in days, up to 300, and the y-axis shows the proportion of patients with relapse from 0 to 1. Two lines represent treatments: a solid line for Cymbalta and a dashed line for placebo, with placebo showing a higher proportion of relapse over time than Cymbalta.*

FDA Label Image

Label Image (Lbl681514734)

Label for Cymbalta 20 mg delayed-release capsule containing duloxetine. The label includes manufacturer Lilly and lists lot number, expiration date 07/14, product code 4734, and a barcode with corresponding NDC 68151-4734. The label states RX only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.